Movement disorders clinical practice · 2025
Treatment-Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T-Cell Therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sanderson John B, Lin Yi-Han, Su Kimmy, Wang Yujie, Portuguese Andrew, Gauthier Jordan, Durbin Meredith, Banerjee Rahul
Аннотация
BACKGROUND: Treatment-emergent motor and neurocognitive adverse events (MNTs) are rare but increasingly well-documented complications of chimeric antigen receptor T-cell (CAR-T) therapy. Here, we describe the development of parkinsonism in four patients who received CAR-T therapy with either B-cell maturation antigen (BCMA)-targeting ciltacabtagene autoleucel for multiple myeloma (n = 3) or CD-19-targeting axicabtagene autoleucel for lymphoma (n = 1).
CASES: We report four cases of parkinsonism in patients who received CAR-T therapy. Two patients had evidence of underlying neurodegenerative parkinsonism, either clinically or through subsequent workup for their movement disorder. All patients received some combination of symptom-directed and immunomodulatory therapies.
CONCLUSION: This report describes features of CAR-T treatment-emergent parkinsonism, introduces parkinsonism as a potential effect of CD-19-targeted CAR-T therapy, and suggests utility of screening for underlying clinical or biomarker signs of pre-existing neurodegenerative parkinsonism prior to CAR-T infusion.
CASES: We report four cases of parkinsonism in patients who received CAR-T therapy. Two patients had evidence of underlying neurodegenerative parkinsonism, either clinically or through subsequent workup for their movement disorder. All patients received some combination of symptom-directed and immunomodulatory therapies.
CONCLUSION: This report describes features of CAR-T treatment-emergent parkinsonism, introduces parkinsonism as a potential effect of CD-19-targeted CAR-T therapy, and suggests utility of screening for underlying clinical or biomarker signs of pre-existing neurodegenerative parkinsonism prior to CAR-T infusion.